All states

GLP-1 weight loss in South Dakota

Visit type
No video visit required
Licensing
South Dakota Board of Medical and Osteopathic Examiners
Updated
Licensed by
South Dakota Board of Medical and Osteopathic Examiners
Telehealth
No video visit required
Semaglutide injections
Available
Tirzepatide injections
Available
Medicaid
Limited coverage
Shipping
2–3 business days

South Dakota residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth. Pallas Health connects you with a board-certified provider licensed in South Dakota who reviews your 5-minute online intake and, if appropriate, sends a prescription that ships to any South Dakota address in 2–3 business days — Sioux Falls, Rapid City, Aberdeen, or the smallest rural route. Compounded semaglutide is $139 first month, then $199 every 4 weeks; compounded tirzepatide is $179 first month, then $299 every 4 weeks.

How telehealth prescribing works in South Dakota

South Dakota permits licensed providers to treat patients through telehealth under SDCL 34-52, which requires a proper provider-patient relationship and, whenever a face-to-face encounter would be required for the same service in person, a real-time audio-visual examination first. The South Dakota-licensed clinician who reviews your intake decides whether your case calls for one; otherwise care proceeds by secure message.

South Dakota requires a licensed South Dakota provider to write any prescription for a South Dakota resident — an out-of-state license is not sufficient. Under SDCL 34-52-3, a provider using telehealth must establish a proper provider-patient relationship — verifying and authenticating the patient's location and identity, obtaining consent, establishing a diagnosis through acceptable medical practices, discussing the diagnosis and treatment options, and ensuring appropriate follow-up care. SDCL 34-52-5 requires a face-to-face examination using real-time audio and visual technology before diagnosis and treatment whenever a face-to-face encounter would otherwise be required for the same service delivered in person; the South Dakota-licensed clinician who reviews your intake decides whether your case calls for one. Your intake is reviewed through our secure clinical platform, and the clinician may follow up by secure message or ask for a video visit if your history calls for it. Every Pallas provider who treats South Dakota patients holds an active South Dakota medical license. GLP-1s are not controlled substances, so South Dakota's additional controlled-substance telemedicine requirements don't apply — but our providers still conduct a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and follow up after initiation to monitor response and titrate the dose.

Medicaid & insurance in South Dakota

South Dakota Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.

Simple cash-pay pricing in South Dakota

No insurance, and the same price in every South Dakota ZIP code. You see your full price during intake, before you pay anything. One plan price covers your US-licensed provider, check-ins, dose adjustments and care-team messaging, with no membership fee. Medication ships free, and nothing is charged until a clinician prescribes. Cancel anytime. Your clinician helps determine which option is appropriate for you.

Compounded

Brand-name

  • Wegovy® injectionsFrom $499
  • Zepbound® injectionsFrom $499
  • Ozempic® injectionsFrom $499
  • Mounjaro® injections$1,099/mo
  • Wegovy® pillFrom $299
  • Foundayo™ pillFrom $299

Semaglutide and tirzepatide prices in South Dakota, plan by plan

Semaglutide vs tirzepatide in South Dakota

Both are once-weekly injections available to South Dakota patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.

In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks — with broadly similar tolerability. That trial predates Wegovy®'s higher 7.2 mg weekly dose, which reached 18.7% average weight loss over 72 weeks in the separate STEP UP trial; separate trials do not provide a direct comparison. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.

Cost and track record differ too: compounded semaglutide renews at $199 every 4 weeks versus $299 for tirzepatide (full terms in the questions below), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in South Dakota — our full semaglutide vs tirzepatide comparison covers the deeper differences.

Cities served in South Dakota

Partner pharmacies ship to every ZIP code in South Dakota, including:

  • Sioux Falls
  • Rapid City
  • Aberdeen
  • Brookings
  • Watertown
  • Mitchell
  • Yankton
  • Pierre
  • Huron
  • Spearfish
  • Vermillion
  • Box Elder

South Dakota GLP-1 questions

Start the online intake (about 5 minutes). A South Dakota-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a US-licensed pharmacy ships it to you in 2–3 business days.

Same intake as semaglutide. If appropriate, a South Dakota-licensed clinician can prescribe compounded tirzepatide or FDA-approved Zepbound® or Mounjaro®, and explains which fits you.

Yes. A South Dakota-licensed clinician can prescribe it for you with a documented clinical reason, and a US-licensed compounding pharmacy prepares it per patient. Brand-name Wegovy® is also available.

Yes. South Dakota nurse practitioners prescribe independently after 1,040 practice hours; newer NPs use a collaborative agreement. GLP-1s are not controlled substances, so they can be prescribed by telehealth.

Several do. Check that its clinicians are licensed in South Dakota, that it uses US-licensed compounding pharmacies, and that it is LegitScript-certified. Pallas serves South Dakota.

No. South Dakota allows a licensed clinician to review your intake by secure message and prescribe without a scheduled video call. They may ask for a video visit only if your history calls for it.

South Dakota Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.

Most South Dakota patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Sioux Falls and Rapid City ship fastest; rural ZIP codes may take an extra day.

One flat cash-pay price, the same in every South Dakota ZIP code, no insurance needed. It covers your clinician, check-ins and messaging, and medication ships free once prescribed.

A South Dakota-licensed clinician decides after reviewing your intake. GLP-1s are generally considered at a BMI of 30 or more, or 27 or more with a condition like high blood pressure.

Wegovy®, Ozempic®, Zepbound® and Mounjaro® are FDA-approved. Compounded semaglutide and tirzepatide are made per patient by US-licensed pharmacies and are not FDA-approved. Your clinician decides.

Yes. Tell your clinician your current medication, dose and everything else you take during intake. If appropriate, they continue you at a comparable dose. Don't change a prescription on your own.

Most patients use a once-weekly injection with a very fine needle. A daily tablet is available on request. Your clinician confirms which form is appropriate for you.

Mostly stomach-related: nausea, constipation or diarrhea, usually mildest when the dose is raised slowly. They are avoided in pregnancy and with a personal or family history of medullary thyroid cancer or MEN2.

You answer health questions online in about 5 minutes. A South Dakota-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a licensed pharmacy ships it in 2–3 business days.

Your first order arrives in 2–3 business days, and most patients start low and step up gradually. Your plan renews on a set schedule so refills arrive before you run out; change or cancel anytime in the portal.

Compounded semaglutide injections are $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.

Compounded tirzepatide injections are $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.

Yes. Wegovy®, Zepbound® and Foundayo™ are FDA-approved for weight management, Ozempic® and Mounjaro® for type 2 diabetes. All are cash-pay: pens from $499 first month, daily pills from $299.

South Dakota Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.

Two cash-pay paths: stay on Wegovy® or Zepbound® from $499 first month, or a compounded plan from $139 first month if a licensed clinician finds it appropriate. Tell your clinician your current dose.

A decision for you and your clinician. Semaglutide costs less and has the longer track record; tirzepatide acts on two gut-hormone receptors instead of one. The comparison above covers the trials.

Pallas serves all of South Dakota with one price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. No video visit is required.

Rule changes affecting South Dakota

  1. 2026-11-09 Louisiana moved to video-visit-required; Washington D.C., North Dakota, New Mexico, and South Dakota moved to async-eligible. The video-required list now stands at 5 states (Arkansas, Louisiana, Mississippi, Rhode Island, and West Virginia); the District is no longer on it.Confirmed with our clinical network's licensing and routing team on 2026-11-06, after its medical group changed on 2026-10-31.
  2. 2026-07-24 Arkansas, Washington D.C., North Dakota, and South Dakota moved to video-visit-required; Kansas moved to async-eligible. The video-required list now stands at 8 jurisdictions (7 states plus Washington, D.C.).Confirmed with our clinical network's licensing and routing team, 2026-07-24.

From our state-by-state rules tracker. Get an email when a rule changes.

Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.